[{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Chiome Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chiome Bioscience \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Chiome Bioscience \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fujifilm holding \/ Sana Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm holding \/ Sana Biotechnology"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe","highestDevelopmentStatusID":"4","companyTruncated":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe"},{"orgOrder":0,"company":"KYORIN PHARMACEUTICAL CO LTD","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"KRP-M223","moa":"MRGPRX2","graph1":"Immunology","graph2":"Preclinical","graph3":"KYORIN PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KYORIN PHARMACEUTICAL CO LTD \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"KYORIN PHARMACEUTICAL CO LTD \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Under this agreement, KYORIN grants Novartis an exclusive worldwide license to develop, manufacture, and commercialize KRP-M223, an MRGPRX2 antagonist for allergic and inflammatory diseases.

                          Product Name : KRP-M223

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 03, 2025

                          Lead Product(s) : KRP-M223

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Under the licensing agreement, Asahi Kasei Pharma has acquired worldwide exclusive rights to develop and commercialize PFKR an anti-CX3CR1 antibody from Chiome.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 20, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Asahi Kasei Pharma

                          Deal Size : $163.5 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Study Phase : Preclinical

                          Sponsor : Foundation for Biomedical Research and Innovation at Kobe

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 16, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Foundation for Biomedical Research and Innovation at Kobe

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : FUJIFILM Cellular Dynamics grants Sana a non-exclusive license under intellectual property rights owned or controlled by FUJIFILM Cellular Dynamics, and will provide iPSC cell lines (including research-grade and/or Good Manufacturing Practices (GMP)-grad...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 16, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Sana Biotechnology

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank